GMAB vs. PFE: Genmab vs. Pfizer Stock Comparison
How do Genmab (GMAB) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Genmab (GMAB) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while PFE is classified in Pharmaceuticals.
Pfizer (PFE) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | GMAB | PFE |
|---|---|---|
| Name | Genmab A/S American Depositary Shares | Pfizer Inc. |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 32.98 billion USD | 167.52 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2009 | June 1, 1972 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GMAB | PFE |
|---|---|---|
| Total Return (1Y) | 91.17% | 28.65% |
| Total Return (3Y, Annualized) | 20.70% | 6.41% |
| Total Return (5Y, Annualized) | 3.98% | -3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GMAB | PFE |
|---|---|---|
| Volatility (1Y, Annualized) | 45.68% | 21.72% |
| Beta (5Y) | 0.72 | 0.35 |
| Max Drawdown (5Y) | -61.79% | -58.96% |
| Avg. Volume (3M) | 4.09M | 33.67M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GMAB | PFE |
|---|---|---|
| Sharpe Ratio (1Y) | 1.90 | 1.12 |
| Sortino Ratio (1Y) | 3.82 | 1.73 |
Profitability
ROE (TTM)
Genmab (GMAB) at 12.07% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for GMAB.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47%
- Max
- 109.18%
- Q3
- 6.23%
- PFE
- 4.47%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Genmab (GMAB) at 16.97% and Pfizer (PFE) at 6.34% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.34%
- Max
- 18.05%
- PFE
- 6.34%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Genmab (GMAB) at 37.15% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.38%
- Max
- 83.12%
- PFE
- 33.38%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GMAB | PFE |
|---|---|---|
| ROE (TTM) | 12.07% | 4.47% |
| ROA (TTM) | 8.24% | 5.59% |
| Net Margin (TTM) | 16.97% | 6.34% |
| Operating Margin (TTM) | 37.15% | 33.38% |
| Gross Margin (TTM) | 92.67% | 74.90% |
Growth
Revenue Growth
Genmab (GMAB) at 19.19% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Both Genmab (GMAB) at -9.23% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | GMAB | PFE |
|---|---|---|
| Revenue Growth (YoY) | 19.19% | -1.65% |
| Revenue Growth (3Y CAGR) | 21.23% | -14.80% |
| EPS Growth (YoY) | -9.23% | -3.55% |
| EPS Growth (3Y CAGR) | 8.48% | -37.12% |
Financial Strength
Current Ratio (MRQ)
Both Genmab (GMAB) at 2.45 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.42
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- PFE
- 1.42
- Min
- 0.10
Debt / Equity (MRQ)
Both Genmab (GMAB) at 0.82 and Pfizer (PFE) at 0.71 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71
- Max
- 1.42
- PFE
- 0.71
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GMAB | PFE |
|---|---|---|
| Current Ratio (MRQ) | 2.45 | 1.42 |
| Debt / Equity (MRQ) | 0.82 | 0.71 |
| Net Debt / EBITDA | 2.45 | 1.97 |
Dividends
Dividend Yield (TTM)
Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.30%
- PFE
- 7.30%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Genmab (GMAB) pays no dividend (payout 0.00%).
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
245.71%
- PFE
- 245.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GMAB | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 7.30% |
| Dividend Payout Ratio (TTM) | 0.00% | 245.71% |
Valuation
P/E Ratio (TTM)
Pfizer (PFE) at 41.99 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.99
- Max
- 85.34
- Q3
- 43.46
- PFE
- 41.99
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Genmab (GMAB) at 7.68 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- PFE
- 2.63
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Genmab (GMAB) at 5.36 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- PFE
- 1.88
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GMAB | PFE |
|---|---|---|
| P/E Ratio (TTM) | 45.84 | 41.99 |
| P/S Ratio (TTM) | 7.68 | 2.63 |
| P/B Ratio (MRQ) | 5.36 | 1.88 |
| Free Cash Flow Yield (TTM) | 2.59% | 7.76% |